Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 19, 2015 1:24 AM ET

Biotechnology

Company Overview of Opsona Therapeutics Limited

Company Overview

Opsona Therapeutics Limited operates as a clinical stage biopharmaceutical company. The company primarily focuses on developing drugs for the treatment of autoimmune/inflammatory diseases and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease, and atherosclerosis. Its portfolio includes OPN-305, a monoclonal/humanized antibody that reduces pro-inflammatory cytokine production associated with heart and kidney diseases, as well as capable of dampening down the body’s immune response to a donated kidney. The company’s development portfolio includes IL-1ß inhibitors. Opsona Therapeutics Limited was founded in 2004 and is based in Dublin, Ireland.

Second Floor

Ashford House

Tara Street

Dublin,  2

Ireland

Founded in 2004

Phone:

353 1 677 0223

Fax:

353 1 677 8949

Key Executives for Opsona Therapeutics Limited

Chief Executive Officer
Age: 53
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Scientific Advisor
Age: 58
Co-Founder, Chief Scientific Officer and Director
Finance Director
Age: 49
Compensation as of Fiscal Year 2014.

Opsona Therapeutics Limited Key Developments

Opsona Therapeutics Limited Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:30 PM

Opsona Therapeutics Limited Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 01:30 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

Opsona Therapeutics Ltd. Commences Part B of Phase II Study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor Renal Transplant Recipients At High Risk of Early Graft Dysfunction

Opsona Therapeutics Ltd. announced the continuation of its double-blind renal transplant study by the initiation of Part B of its adaptive phase II clinical trial in Extended Criteria Donors (ECD) renal transplant recipients at high risk of early graft dysfunction with its lead drug candidate OPN-305. Based on the completion of Part A of this double blind study, OPN-305 was well tolerated and deemed to be safe by the data and safety monitoring board across all dose groups with no evidence of increased risk of infection in these highly immuno-suppressed patients. The company is proceeding with Part B in a modified patient population evaluating ECD-only recipients. ECD kidneys make up the large pool of the cadaveric donor population. Currently up to 45% of ECD kidneys are discarded resulting in a significant deficit in supply versus demand. OPN-305 has the opportunity to turn borderline non-transplantable organs into viable kidneys and functioning grafts resulting in fewer ECD discards, driving an overall increase in the number of deceased donor transplants.

Opsona Therapeutics Mulls IPO

Opsona Therapeutics Limited may consider launching an initial public offer (IPO) after completing a multi-million euro experiment. "The trials will start soon, in Q1 anyway, and will run this year and probably to the end of next year. Afterwards we will look at funding, we might look at a strategic partnership or at an IPO, it will depend on the data we get," Chief Executive Officer, Martin Welschof said.

Similar Private Companies By Industry

Company Name Region
Labcoat Limited Europe
The Centre for Human Proteomics Europe
Genable Technologies Ltd. Europe
Grifols Worldwide Operations Ltd. Europe
Genzyme Ireland Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Opsona Therapeutics Limited, please visit www.opsona.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.